Cover Image
Market Research Report

Women's Health - Medical Devices Pipeline Assessment, 2019

Published by GlobalData Product code 564948
Published Content info 603 Pages
Delivery time: 1-2 business days
Price
Back to Top
Women's Health - Medical Devices Pipeline Assessment, 2019
Published: December 16, 2019 Content info: 603 Pages
Description

GlobalData's Medical Devices sector report, "Women's Health - Medical Devices Pipeline Assessment, 2019" provides an overview of Women's Health currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Women's Health pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Women's Health under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Women's Health and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Women's Health under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date
Table of Contents
Product Code: GDME0859EPD

Table of Contents

  • 1.1 List of Tables 17
  • 1.2 List of Figures 28

2 Introduction 29

  • 2.1 Women's Health Overview 29

3 Products under Development 30

  • 3.1 Women's Health - Pipeline Products by Stage of Development 30
  • 3.2 Women's Health - Pipeline Products by Territory 31
  • 3.3 Women's Health - Pipeline Products by Regulatory Path 33
  • 3.4 Women's Health - Pipeline Products by Estimated Approval Date 34
  • 3.5 Women's Health - Ongoing Clinical Trials 35

4 Women's Health - Pipeline Products under Development by Companies 36

  • 4.1 Women's Health Companies - Pipeline Products by Stage of Development 36
  • 4.2 Women's Health - Pipeline Products by Stage of Development 41

5 Women's Health Companies and Product Overview 47

  • 5.1 AblaCare Company Overview 47
    • 5.1.1 AblaCare Pipeline Products & Ongoing Clinical Trials Overview 47
  • 5.2 AdneXXA LLC Company Overview 50
    • 5.2.1 AdneXXA LLC Pipeline Products & Ongoing Clinical Trials Overview 50
  • 5.3 Advanced Prenatal Therapeutics, Inc. Company Overview 51
    • 5.3.1 Advanced Prenatal Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 51
  • 5.4 Advanced Tactile Imaging Inc Company Overview 52
    • 5.4.1 Advanced Tactile Imaging Inc Pipeline Products & Ongoing Clinical Trials Overview 52
  • 5.5 AEGEA Medical Inc Company Overview 55
    • 5.5.1 AEGEA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 55
  • 5.6 Aethlon Medical Inc Company Overview 56
    • 5.6.1 Aethlon Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 56
  • 5.7 Agile Therapeutics Inc Company Overview 57
    • 5.7.1 Agile Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 57
  • 5.8 Allergan Plc Company Overview 60
    • 5.8.1 Allergan Plc Pipeline Products & Ongoing Clinical Trials Overview 60
  • 5.9 AltaScience Limited Company Overview 62
    • 5.9.1 AltaScience Limited Pipeline Products & Ongoing Clinical Trials Overview 62
  • 5.10 Alydia Health Inc Company Overview 63
    • 5.10.1 Alydia Health Inc Pipeline Products & Ongoing Clinical Trials Overview 63
  • 5.11 Amniotix Technologies Ltd Company Overview 66
    • 5.11.1 Amniotix Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 66
  • 5.12 ANALYTICA PTY LTD Company Overview 67
    • 5.12.1 ANALYTICA PTY LTD Pipeline Products & Ongoing Clinical Trials Overview 67
  • 5.13 Aneeve Nanotechnologies LLC Company Overview 68
    • 5.13.1 Aneeve Nanotechnologies LLC Pipeline Products & Ongoing Clinical Trials Overview 68
  • 5.14 Aspivix SA Company Overview 69
    • 5.14.1 Aspivix SA Pipeline Products & Ongoing Clinical Trials Overview 69
  • 5.15 Bayer AG Company Overview 70
    • 5.15.1 Bayer AG Pipeline Products & Ongoing Clinical Trials Overview 70
  • 5.16 Baystate Medical Center Company Overview 72
    • 5.16.1 Baystate Medical Center Pipeline Products & Ongoing Clinical Trials Overview 72
  • 5.17 Becton Dickinson and Co Company Overview 73
    • 5.17.1 Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview 73
  • 5.18 BeFree! Company Overview 76
    • 5.18.1 BeFree! Pipeline Products & Ongoing Clinical Trials Overview 76
  • 5.19 BellaSeno GmbH Company Overview 77
    • 5.19.1 BellaSeno GmbH Pipeline Products & Ongoing Clinical Trials Overview 77
  • 5.20 Bewell Connect Corp Company Overview 78
    • 5.20.1 Bewell Connect Corp Pipeline Products & Ongoing Clinical Trials Overview 78

6 Women's Health- Recent Developments 289

  • 6.1 Nov 19, 2019: Edan to highlight its new developments at MEDICA 2019 289
  • 6.2 Nov 19, 2019: Clinical Innovations hires Rebecca Liu as VP, general manager for CI Medical Instruments in China 289
  • 6.3 Nov 18, 2019: A new self-use innovative treatment for pelvic organ prolapse in women (POP) designed by ConTIPI Medical 290
  • 6.4 Nov 18, 2019: Barbro Friden steps down as a member of the board of Vitrolife 291
  • 6.5 Nov 14, 2019: Merck acquires Calporta Therapeutics for $576m 291
  • 6.6 Nov 14, 2019: INVO Bioscience reports third quarter 2019 financial results 291
  • 6.7 Nov 13, 2019: BellaSeno and Evonik to launch 3D-printed absorbable breast scaffold 293
  • 6.8 Nov 13, 2019: Thermo Fisher Scientific opens Customer Solution Center in China to support pharmaceutical and biopharmaceutical laboratories 294
  • 6.9 Nov 13, 2019: Atossa Genetics announces third quarter 2019 financial results and provides company update 294
  • 6.10 Nov 13, 2019: Thermo Fisher Scientific announces membership of the Pistoia Alliance 296

7 Appendix 600

  • 7.1 Methodology 600
  • 7.2 About GlobalData 603
  • 7.3 Contact Us 603
  • 7.4 Disclaimer 603

List of Tables

  • Table 1: Women's Health - Pipeline Products by Stage of Development
  • Table 2: Women's Health - Pipeline Products by Territory
  • Table 3: Women's Health - Pipeline Products by Regulatory Path
  • Table 4: Women's Health - Pipeline Products by Estimated Approval Date
  • Table 5: Women's Health - Ongoing Clinical Trials
  • Table 6: Women's Health Companies - Pipeline Products by Stage of Development
  • Table 7: Women's Health - Pipeline Products by Stage of Development
  • Table 8: AblaCare Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: AblaCare Kit - Product Status
  • Table 10: AblaCare Kit - Product Description
  • Table 11: AblaCare - Ongoing Clinical Trials Overview
  • Table 12: AblaCare Kit - ULTRA Study: A Feasibility, Prospective, Multicenter, Single-arm Trial of the AblaCare Device in Transvaginal Ablation of Ovarian Tissue Under Ultrasound Visualisation in Women with Polycystic Ovary Syndrome (PCOS)
  • Table 13: AdneXXA LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 14: Reusable Contraception Device - Product Status
  • Table 15: Reusable Contraception Device - Product Description
  • Table 16: Advanced Prenatal Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 17: Targeted Apheresis Column for Preeclampsia (TAC-PE) - Product Status
  • Table 18: Targeted Apheresis Column for Preeclampsia (TAC-PE) - Product Description
  • Table 19: Advanced Tactile Imaging Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 20: Antepartum Tactile Imager - Product Status
  • Table 21: Antepartum Tactile Imager - Product Description
  • Table 22: Cervix Monitor - Product Status
  • Table 23: Cervix Monitor - Product Description
  • Table 24: Restore-IT - Product Status
  • Table 25: Restore-IT - Product Description
  • Table 26: AEGEA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 27: Next-Generation Adaptive Vapor Ablation System - Product Status
  • Table 28: Next-Generation Adaptive Vapor Ablation System - Product Description
  • Table 29: Aethlon Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 30: HER2osome - Product Status
  • Table 31: HER2osome - Product Description
  • Table 32: Agile Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 33: AG200-ER Patch - Product Status
  • Table 34: AG200-ER Patch - Product Description
  • Table 35: AG200-SP Patch - Product Status
  • Table 36: AG200-SP Patch - Product Description
  • Table 37: AG890 Patch - Product Status
  • Table 38: AG890 Patch - Product Description
  • Table 39: Allergan Plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 40: Norethindrone Transdermal Delivery System - Product Status
  • Table 41: Norethindrone Transdermal Delivery System - Product Description
  • Table 42: Smooth 133 Plus TE - Product Status
  • Table 43: Smooth 133 Plus TE - Product Description
  • Table 44: AltaScience Limited Pipeline Products & Ongoing Clinical Trials Overview
  • Table 45: AltaSeal - Product Status
  • Table 46: AltaSeal - Product Description
  • Table 47: Alydia Health Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 48: InPress Postpartum Hemorrhage Intrauterine Device - Product Status
  • Table 49: InPress Postpartum Hemorrhage Intrauterine Device - Product Description
  • Table 50: Alydia Health Inc - Ongoing Clinical Trials Overview
  • Table 51: InPress Postpartum Hemorrhage Intrauterine Device - Potential Approach to Treat Postpartum Hemorrhage Using InPress Postpartum Hemorrhage Intrauterine Device
  • Table 52: InPress Postpartum Hemorrhage Intrauterine Device - Prospective, Single Arm Pivotal Clinical Trial Designed to Assess the Safety and Effectiveness of the Jada System in Treating Primary Postpartum Hemorrhage
  • Table 53: Amniotix Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 54: Amniotic Fluid Spectral Monitoring Device - Product Status
  • Table 55: Amniotic Fluid Spectral Monitoring Device - Product Description
  • Table 56: ANALYTICA PTY LTD Pipeline Products & Ongoing Clinical Trials Overview
  • Table 57: PeriCoach System - Pelvic Organ Prolapse - Product Status
  • Table 58: PeriCoach System - Pelvic Organ Prolapse - Product Description
  • Table 59: Aneeve Nanotechnologies LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 60: Hormone Level Monitor - Product Status
  • Table 61: Hormone Level Monitor - Product Description
  • Table 62: Aspivix SA Pipeline Products & Ongoing Clinical Trials Overview
  • Table 63: Aspivix Device - Product Status
  • Table 64: Aspivix Device - Product Description
  • Table 65: Bayer AG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 66: LNG-IUS16 - Product Status

List of Figures

  • Figure 1: Women's Health - Pipeline Products by Stage of Development
  • Figure 2: Women's Health - Pipeline Products by Territory
  • Figure 3: Women's Health - Pipeline Products by Regulatory Path
  • Figure 4: Women's Health - Pipeline Products by Estimated Approval Date
  • Figure 5: Women's Health - Ongoing Clinical Trials
Back to Top